About | Aseptuva

Current development stage

Proof-of-Concept

We have established Proof-of-Concept (in-vitro) for safety and efficacy up to 99.999% for various bacterial and fungal species causing HAI. These studies were funded by Innosuisse and Switzerland Innovation and conducted at ZHAW Wadenswil and University of Zurich.

Intellectual Property

Our patent protects the overall technology for different medical applications, while we are extending the patent family with individual devices focused on a specific application.

Product development

Our functional prototypes are being used for Preclinical validation and Usability studies. Their design & fabrication is supported by EU Horzion 2020 MedPhab project with Philips Innovation Services, NL and Tyndall National Institute, Ireland.

Customer Interest

Our future customers include hospitals in Switzerland, UK, and US, from whom several Letters of Intent have been signed.

Meet our team

Meet some of the visionaries behind Aseptuva, driving innovation for a safer healthcare future.

Open positions

Master’s degree in Banking and Finance from the University of Zurich - gaining further entrepreneurial Know-how at Seoul National University, South Korea and Singapore Management University. Experience in Event Management including festivals with >25,000 visitors, Good Clinical Practice, Wealth Management. Responsible for Business Development, Fundraising & Operations.

Henry Twerenbold

CEO & Co-Founder

Business Development, Fundraising & Operations

PhD in Computational Biomechanics from the Swiss Federal Institute of Technology (ETH) Zurich, with additional skills in implementation of QMS compliant with ISO 13485:2016, Good Clinical Practice, Biocompatibility testing. Responsible for Biological Evaluation, Quality Assurance & Product Development.

Eashan Saikia

CTO & Co-Founder

Biological Evaluation, Quality Assurance & Product Development

BSc. in Biomedical Engineering from University Carlos III of Madrid and BSc. in Optics and Optometry, with 7+ years of experience in healthcare. She is a former biomedical researcher at CSIC and ETH Zurich, contributing to projects in Visual Optics, Biophotonics & Product Development.

Diana Canosa Tajes

Biomedical Engineer

Visual Optics, Biophotonics & Product Development

M(med)Sc. in Bioentrepreneurship from Karolinska Institute and a BSc. in Medical Technology. Combines academic and practical experience with Medical Device Engineering, Manufacturing, Corporate Venture Capital & Business Development.

Leon Tobler

US Business Analyst & Investor Relations

Medical Device Engineering, Manufacturing, Corporate Venture Capital & Business Development

MSc. in Pharmaceutical Formulation and Entrepreneurship at University College London. Knowledge in Finance & Commercialization within the Biotechnology/Medicine sectors and the overall startup environment.

Alexia Lamprakaki

UK Healthcare strategist

Finance & Commercialization within the Biotechnology/Medicine sectors

Advisory board

Prof. Dr. med. Hugo Sax

Infectious Diseases

Former Head of Infection Prevention and Hospital Epidemiology University Hospital Zurich & Board Member and Ex-President Swissnoso - Swiss National Centre for Infection Prevention

Prof. em. Dr. med. Hans Pargger

Customer Advisor Switzerland

Former Director, Chief-Physician Intensive Care Unit, University Hospital Basel & Former President of Certification Commission of the Swiss Society of Intensive Care Medicine

Prof. Dr. Michael Hengartner

R&D Strategy

President of the ETH Board - Board of the Swiss Federal Institutes of Technology

Leo den Hartog

Medtech / QMS Strategy

Senior Director Reliability Sonova Group

Dr. Fabian Unteregger

Network

Co-Founder and Co-President Swiss Healthcare Startups & Founding Member ETH Circle, Comedian & Entrepreneur